MediPharm Labs Corp (MEDIF) reports record adjusted EBITDA and positive net income, driven by a 26% surge in international medical cannabis revenue.

MediPharm Labs Corp (MEDIF) reports a return to positive adjusted EBITDA, strong international growth, and a robust balance sheet, despite facing domestic revenue headwinds.

MediPharm Labs (OTC:MEDIF) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. View the webcast at https://events.q4inc.com/attendee/116870256 Summary MediPharm Labs reported Q1 2026 revenue of CAD 9.0 million, a decrease from CAD 10.8 million in Q1

MediPharm Labs (TSX:LABS) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://events.q4inc.com/attendee/116870256 Summary MediPharm Labs reported Q1 2026 revenue of $9.0 million, down from $10.8 million in Q1 2025, with a gross profit of $3.3 million

While the Canadian market navigates a landscape filled with uncertainties, particularly around energy supply disruptions and geopolitical tensions, investors are advised to maintain a balanced approach between growth and value sectors. Despite being considered somewhat outdated, penny stocks continue to offer intriguing opportunities for those willing to explore smaller or newer companies that may provide both affordability and growth potential. In this article, we will examine three notable...

MediPharm Labs Corp (MEDIF) reports 8% annual revenue growth and improved profitability, driven by a robust international medical cannabis segment.

The Canadian market has shown signs of stabilization, with the unemployment rate declining to 4.3% and inflation easing closer to the target range, despite ongoing uncertainties around trade agreements. In this context, penny stocks—typically representing smaller or newer companies—offer intriguing opportunities for investors looking for growth at lower price points. While often considered a niche investment area, these stocks can still provide value when backed by strong financial health and...

MediPharm Labs (LABS.TO) on Monday announced that David Pidduck will be stepping down from his role

Canadian equities have recently reached new record highs, buoyed by supportive signals from the Bank of Canada and the Federal Reserve. In this context, penny stocks—though a somewhat outdated term—still represent an intriguing investment area, often involving smaller or newer companies that can offer growth potential at lower price points. By focusing on those with robust financials and clear growth trajectories, investors may uncover promising opportunities within this niche market segment.

Key Takeaways; Cannabis Sector Curaleaf Plans to Move into Virginia with $110 Million Acquisition of Competitor’s Assets Aurora Expanded Australian Footprint Through a New Distribution Deal MediPharm Labs Entered French Market with First Cannabis Shipment High Tide Launched First European Canna Cabana in Berlin Key Takeaways; Psychedelic Sector NRx Pharmaceuticals Advanced Preservative-Free Ketamine and Expanded […]